Shenlian Biomedical passes veterinary GCP inspection
Shanghai Shenlian Biomedical (SSE:688098) announced it has successfully passed the Good Clinical Practice (GCP) supervision and inspection for veterinary drugs conducted by the Ministry of Agriculture and Rural Affairs. This achievement expands the company's clinical trial capabilities to include animal biological products for pets and cattle, in addition to existing qualifications for swine. The company said this milestone strengthens its research and development capabilities, supports its diversified growth strategy, and bolsters its contribution to animal health in China. The Board of Directors cautions investors to be aware of investment risks.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Shen Lian Biomedical Corporation publishes news
Free account required • Unsubscribe anytime